Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (202)	2/5/2001 10:48:48 PM
From: scaram(o)uche	Respond to of 539

Good friend just went to work for Gryphon. Shows they have good taste....... Monday February 5, 8:14 pm Eastern Time Press Release SOURCE: Gryphon Sciences Gryphon Sciences and Geneva Proteomics Announce a Proteomics Collaboration SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire/ -- Gryphon Sciences and Geneva Proteomics (``GeneProt'') announced the signing of a collaboration agreement for the chemical synthesis of proteins identified by proteomic analysis of chosen biological fluids, cells and tissues in both healthy and sick individuals. GeneProt will use its parallel, high-throughput proteomic analysis technologies to identify proteins of commercial interest. These proteins in turn will be made in small amounts as well as in precision-labeled forms by GeneProt using Gryphon's chemical protein synthesis technology. GeneProt will provide access to its databases to potentially facilitate Gryphon's selection of proteins for chemical enhancement of their therapeutic behavior. GeneProt and Gryphon will also collaborate on the development of next-generation chemical protein synthesis technologies. The financial terms of the collaboration were not disclosed. Friedhelm Blobel, President and CEO of Gryphon Science, stated: ``GeneProt's position as a leader in proteomics make it an ideal partner for Gryphon. The massive amounts of new data generated by high-throughput analysis of healthy and diseased proteomes will give rise to multiple new protein targets of commercial interest to the biotechnology and pharmaceutical industries. Gryphon's technology is well-suited to make these proteins. We believe our technology will give GeneProt and its collaborators a competitive advantage in the emerging proteomics arena, and Gryphon a competitive advantage in our own drug development programs.'' Gryphon Sciences is a privately held company based in South San Francisco, California. Gryphon is a biopharmaceutical company that is developing performance-enhanced protein therapeutics through chemistry for the health care industry. The foregoing press release may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These forward-looking statements will be subject to risks and uncertainties that may cause actual results to differ materially. Gryphon Sciences disclaims any intent or obligation to update these forward-looking statements. SOURCE: Gryphon Sciences